CHICAGO — Glucagon-like peptide-1 receptor agonists lowered the risk for obesity-related cancers compared with bariatric surgery among individuals with a BMI of at least 35, according to data presented at ASCO Annual Meeting.
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) conferred a greater risk reduction in all-cause mortality, despite inferior weight loss results when compared with bariatric surgery, researchers noted.
“Both glucagon-like peptide-1 receptor agonist therapy and bariatric surgery reduced the risk [for] weight-related cancer as compared [with]